Medical liability coverage for Texas physicians

Click on the drug names below to view the full risk alert.

---

• Lo/Ovral-28 (Norgestrel/EthinylEstradiol) Tablets — recall
• Topical hair regrowth products — recall
• Bedford Laboratories Polymyxin B For Injection USP And vecuronium bromide For Injection — recall
• Multaq (dronedarone) — increased risk of death or serious cardiovascular events
• FDA labeling changes for 28 products
• Prescription drug samples
• FDA labeling changes for 22 products
• Qualitest Pharmaceuticals oral contraceptives — recall
• Reclast (zoledronic acid) — new contraindication and updated warning
• Celexa — abnormal heart rhythms associated with high doses
• Methylene Blue — possible CNS reactions when given to patients taking psychiatric medications
• Diflucan (fluconazole) — long-term, high-dose use may be associated with birth defects
• Zyvox (linezolid) — possible CNS reactions when given to patients taking psychiatric medications
• FDA warning — counterfeit morning after pill
• Multaq (dronedarone) — increased risk of death or serious cardiovascular events
• FDA labeling changes for 50 products
• Tamiflu (oseltamivir phosphate) for oral suspension — new concentration
• 5-alpha reductase inhibitors (5-ARIs) — increased risk of prostate cancer
• Valproate products — risk of impaired cognitive development in children exposed in utero
• FDA labeling changes for 47 products
• Birth control pills containing drospirenone — risk of blood clots
• TNF blockers, Azathioprine, Mercaptopurine — update
• Topiramate (Topamax) — recall
• Citalopram, finasteride — recall
• Irinotecan Hydrochloride Injection — recall
• Topiramate (Topamax) — risk of oral clefts in newborns
• Proton pump inhibitor drugs (PPIs) — long-term use associated with low magnesium levels
• Warfarin sodium tablets (Jantoven), 3mg — recall
• Albuterol Sulfate Inhalation Solution 0.083%, 3 mL unit dose vials — recall
• Avastin (bevacizumab) — FDA recommends removal of breast cancer indication
• Darvon, Darvocet (propoxyphene) — voluntary withdrawal
• Methotrexate Injection, 50mg/2mL and 250mg/10mL Vials — recall
• Heparin Sodium (B.Braun) — recall
• Fentanyl transdermal system — recall
• FDA restricts access to the diabetes drug rosiglitazone (Avandia)
• Sibutramine (Meridia) — withdrawal
• Octagam (immune globulin intravenous — human) 5% liquid preparation — withdrawal
• Epogen and Procrit (epoetin alfa) — recall
• Gadolinium-based contrast agents — risk of nephrogenic systemic fibrosis